Revvity, Inc.

RVTY · NYSE · USD

Can three quarters of improving pharma orders and double-digit diagnostics growth sustain 4% to 5% organic growth, or does the recovery still rest on customer budgets that keep slipping?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Diagnostics growth outpaces the company

    Diagnostics, led by newborn screening and reproductive health, is growing faster than the rest of the company even where birth rates are flat or falling.

  • Pharma and biotech order recovery

    Orders from pharma and biotech customers have improved for three quarters, and management expects AI lab build-outs to add demand for screening instruments and reagents.

  • China diagnostics divestiture

    Selling the China immunodiagnostics business removes a low-growth, low-margin operation and leaves a company with a cleaner growth and margin profile.

  • Cost cuts and share buybacks

    Cost programs and share repurchases raise earnings per share even on modest revenue growth, and cash conversion has run well above the company's history.

Bear case

  • Slow underlying revenue growth

    Organic growth has been close to flat for years and each expected pickup has slipped, so the improved guidance still depends on customers loosening their budgets.

  • Software revenue is lumpy

    Software revenue swings with contract renewal timing and can fall by double digits in a quarter, so its reported growth says little about underlying demand.

  • One-time tariff refunds

    Part of the latest earnings beat came from one-time tariff refunds, so the quarter's profit rate overstates what the business earns on an ongoing basis.

  • Instrument demand and federal funding

    Instruments have declined for three years and academic and government purchases depend on federal funding decisions that remain unsettled.

Bull and bear points

Growth & Execution

In short: Diagnostics and pharma orders are improving, while software and instrument sales remain uneven.

Bull · 3

  • Diagnostics grows 11% organically once China is excluded

    Diagnostics revenue was $371 million, up 4.7% as reported, and management puts pro forma organic growth at 11% once China immunodiagnostics is excluded, making it the company's most reliable growth segment.

    Q2 FY2026 call

  • AI-related orders build the strongest instrument backlog in years

    Management says high-content screening orders are outpacing production capacity and that instrument backlog entering the third quarter is the strongest in three to four years.

    Q2 FY2026 call

  • Full-year organic growth guidance raised twice in six months

    In February management guided 2% to 3% organic growth for 2026 and called the environment fluid; in August it guided 4% to 5% and said a recovery is underway.

    Tone shiftQ4 FY2025 → Q2 FY2026
Bear · 2

  • Software revenue falls about 20% on contract timing

    Signals software fell about 20% organically in the second quarter on renewal timing and a hard comparison, so its reported growth swings widely from quarter to quarter.

    Q2 FY2026 call

  • Academic and government purchases hinge on federal funding

    Sales to academic and government customers have declined, and management cites U.S. funding and regulatory proposals as reasons customers stay cautious, which limits recovery in instruments and reagents.

    10-K, filed 2026-02-24

Profitability & Financial Strength

In short: Cash conversion is strong and margins are rising, though recent profit gains lean on one-time tariff refunds.

Bull · 2

  • Margin outlook raised on completed cost programs

    Management's 2026 adjusted operating margin target has gone from 28% to 28.7%, helped by excluding China immunodiagnostics and by cost programs now largely complete.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Free cash flow covers buybacks and debt repayment

    Free cash flow of $558 million over the last twelve months, equal to 19% of revenue, has funded share repurchases and repayment of a bond that matured in July.

    Q2 FY2026 call
Bear · 2

  • Tariff refunds supplied half the second-quarter earnings beat

    About half of the second-quarter earnings upside came from $16 million of one-time tariff refunds, so the 29.3% adjusted operating margin overstates the ongoing margin rate.

    Q2 FY2026 call

  • Five-year revenue growth of 1.4% limits margin leverage

    Revenue compounded at only 1.4% a year from FY2020 to FY2025, so fixed costs spread slowly and margin gains have come from cost cuts rather than volume.

    Filed financials

Market Position

In short: Screening instruments and Signals software support pricing, while China exposure and trade policy carry risk.

Bull · 2

  • Non-commoditized instruments hold pricing in reagents

    Management says it took reagent share without margin dilution, which matters because reagent volume carries much of the incremental profit in life sciences.

    Q4 FY2025 call

  • Signals software is installed across large pharma

    Signals is used by nearly every major pharma company for preclinical data work, giving Revvity an installed base to sell AI features such as Synthetica and BioDesign into.

    Q4 FY2025 call
Bear · 1

  • Management abandons its China diagnostics growth plan

    A year ago China immunodiagnostics was expected to return to low single-digit growth; in May management instead agreed to sell the business to a local buyer group.

    Tone shiftQ3 FY2025 → Q1 FY2026